Atlas FDA

RADIESSE INJECTABLE IMPLANT

FDA premarket approval P050037/S028 · decided 2012-06-20

Approval details

PMA number
P050037
Supplement
S028
Supplement type
Normal 180 Day Track No User Fee
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
RADIESSE INJECTABLE IMPLANT
Generic name
Implant, dermal, for aesthetic use
Applicant
Merz North America, Inc.
Date received
2011-03-30
Decision date
2012-06-20
Days to decision
448 days
Decision code
APPR
Product code
LMH
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Franksville, WI
Statement
APPROVAL FOR THE ADDITION OF SAFETY AND EFFECTIVENESS CLINICAL DATA AND POST-MARKETING SURVEILLANCE DATA FROM THE POST APPROVAL STUDIES PERFORMED AS A CONDITION OF APPROVAL FOR THE RADIESSE INJECTABLE IMPLANT. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THETRADE NAME RADIESSE INJECTABLE IMPLANT AND IS INDICATED FOR SUBDERMAL IMPLANTATION FOR THE CORRECTION OF MODERATE TO SEVERE FACIAL WRINKLES AND FOLDS, SUCH AS NASOLABIAL FOLDS AND IT IS ALSO INTENDED FOR RESTORATION AND/OR CORRECTION OF TH

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
DESCRIBE PFD Patch (K172689)Merz North America, Inc.2017-11-29